Crizotinib

CHEMBL601719 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

450.3 g/mol

LogP

3.7

Phase

4

An oral tyrosine kinase inhibitor that blocks ALK, ROS1, and MET signaling proteins driving certain lung and other cancers, particularly non-small cell lung cancer with ALK or ROS1 gene rearrangements. It was one of the first targeted therapies to demonstrate dramatic responses based on tumor genetics.

Peso Molecular

450,3000 g/mol

LogP

3,70

TPSA

78,00 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Mecanismo de Ação

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl

InChI

InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

Molecular Formula

C21H22Cl2FN5O

HBD / HBA

2 / 6

Ligações Rotacionáveis

5

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An oral tyrosine kinase inhibitor that blocks ALK, ROS1, and MET signaling proteins driving certain lung and other cancers, particularly non-small cell lung cancer with ALK or ROS1 gene rearrangements. It was one of the first targeted therapies to demonstrate dramatic responses based on tumor genetics.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Crizotinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL601719. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11626560. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Crizotinib no PillFYI

Estrutura

Dados Rápidos

Fórmula: C21H22Cl2FN5O
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.